Beyond adrenal suppression: a comprehensive post-marketing safety profile of etomidate from real world data
Frontiers in Medicine · 07.07.2026 · 13
DOI: 10.3389/fmed.2026.1780171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 07.07.2026. Verfasst von Huiyi Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, the Eighth Affiliated Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, C…. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Etomidate is a widely used intravenous anesthetic, yet concerns persist regarding its potential for adverse drug reactions (ADRs) beyond well-known adrenal suppression. Pre-marketing trials may not fully capture its long-term or rare safety profile, necessitating continuous post-marketing surveillance.
Methods
A retrospective pharmacovigilance study was performed based on the U.S. FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q2 2025). Disproportionality analysis using ROR, PRR, BCPNN and EBGM algorithms was conducted and the corresponding 95% CIs were calculated. ADRs meeting the criteria of all four algorithms were considered positive signals significantly associated with the target drug.
Results
Totally 318 ADRs were acquired, of which 59 preferred terms (PTs) and two system organ classes (SOCs) met four algorithm criteria. In addition to known cardiovascular, muscular and adrenal related PTs, novel positive signals included cardiac arrest ( n = 33), seizure ( n = 12), drug abuse ( n = 10), hypokalaemia ( n = 9) and bruxism ( n = 9) were found to be correlated with etomidate. As for SOCs, cardiac disorders ( n = 100) remains significantly associated with etomidate while endocrine disorders ( n = 38) was uncovered as a novel signal.
Conclusions
This study confirmed known risks and identified novel ADRs of etomidate. These findings underscore the need for heightened clinical vigilance and further investigation into its long-term safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, the Eighth Affiliated Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China.
- Senior Department of Traditional Chinese Medicine, the Sixth Medical Center of PLA General Hospital, Beijing, China.
- Department of Anesthesiology, the Eighth Affiliated Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China.
Zitieren
APA
Deng, H., Lai, W., Xiang, Y., Wang, Z., Liang, J., Zhang, Y., & Liang, J. (2026). Beyond adrenal suppression: a comprehensive post-marketing safety profile of etomidate from real world data. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1780171
Vancouver
Deng H, Lai W, Xiang Y, Wang Z, Liang J, Zhang Y, et al. Beyond adrenal suppression: a comprehensive post-marketing safety profile of etomidate from real world data. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1780171
BibTeX
@article{Deng2026,
author = {Deng, Huiyi and Lai, Wujiang and Xiang, Ying and Wang, Zewen and Liang, Jiemei and Zhang, Yiwen and Liang, Jiale},
title = {Beyond adrenal suppression: a comprehensive post-marketing safety profile of etomidate from real world data},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1780171}
}
EUVIMED